共 64 条
- [51] Oesterling J.E., Jacobson S.T., Cjite C.G., Et al., Serum prostatespecific antigen in a community-based population of healthy men, JAMA, 270, pp. 860-864, (1993)
- [52] Littrup P.J., Prostate cancer in African-American men [editorial], 31, pp. 139-141, (1997)
- [53] Littrup P.J., Sparschu R.A., Transrectal ultrasound and prostate cancer risks: The “tailored” prostate biopsy, Cancer, 75, pp. 1805-1813, (1995)
- [54] Powell I.J., Banerjee M., Novallo M., Et al., Should the age-specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years?, J Urol, 163, pp. 146-149, (2000)
- [55] Moul J.W., Curability of prostate cancer in African Americans: Implications for Neoadjuvant/Adjuvant hormonal therapy, Mol Urol, 2, (1998)
- [56] Moul J.W., PSA thresholds for prostate cancer detection, JAMA, 278, (1997)
- [57] Carter H.B., Et al., Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer, JAMA, 277, pp. 1456-1460, (1997)
- [58] Catalona W.J., Screening for prostate cancer [letter], N Eng J Med, 334, pp. 666-667, (1996)
- [59] Bullock A.D., Harmon T., Smith D.S., Basler J.W., Prostate cancer screening in younger men [abstract], J Urol, S66, (1997)
- [60] Catalona W.J., Smith D.S., Ornstein D.K., Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ngmL and benign prostate examination, JAMA, 277, pp. 1452-1455, (1997)